Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed.

1. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration--a phase IV randomised clinical trial with ranibizumab: the FLUID study.BMC ophthalmology · 2016
   Trial
2. Long-term outcomes of the observe-and-plan regimen in treating neovascular age-related macular degeneration: a retrospective real-life analysis.Eye (London, England) · 2025
   Article
3. Short-term response to anti-VEGF as indicator of visual prognosis in refractory age-related macular degeneration.Eye (London, England) · 2024
   Observational
4. Modifiable Determinants of Satisfaction with Intravitreal Treatment in Patients with Neovascular Age-Related Macular Degeneration.Drugs & aging · 2022
   Observational
5. TREATMENT DEFERRAL DURING COVID-19 LOCKDOWN: Functional and Anatomical Impact on Patients With Neovascular Age-Related Macular Degeneration.Retina (Philadelphia, Pa.) · 2022
   Article
6. Patient satisfaction following a switch from treat-and-extend to observe-and-plan regimen in age-related macular degeneration.BMJ open ophthalmology · 2022
   Article
7. Revisiting the Utility of Dilated Fundus Exams in Patients with Neovascular Age-Related Macular Degeneration Receiving Regular Intravitreal Injections.Clinical ophthalmology (Auckland, N.Z.) · 2021
   Article
8. Safety and clinical effectiveness of intravitreal administration of bevacizumab (LumiereExperimental and therapeutic medicine · 2020
   Article
9. Use of Imaging Modalities in Real Life: Impact on Visual Acuity Outcomes of Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration in Germany.Journal of ophthalmology · 2020
   Article
10. MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen.Retina (Philadelphia, Pa.) · 2019
    Observational
11. Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2017
    Article
12. Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept.Drugs & aging · 2015
    Review

Corrections and comments

• Erratum for
  Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results.2015

Authors and funding

8 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.